This grant aims to boost awareness, knowledge, surveillance, and patient care for Alpha-gal Syndrome in the US by supporting professional collaboration, public education, and tracking of the condition.
Funder: Centers for Disease Control - NCEZID
Due Dates: June 7, 2026 (Optional letter of intent) | June 19, 2026 (Full application, 11:59 p.m. ET)
Funding Amounts: $25,000–$1,000,000 per year per award; up to 5 years; estimated total program funding $10,000,000–$25,000,000; 1–5 awards expected
Summary: Supports projects to increase awareness, surveillance, and knowledge-sharing about Alpha-gal Syndrome (AGS) in the US through professional networks, education, and enhanced surveillance.
Key Information: Research activities are unallowable; applicants must include Strategy 1 (network formation), with Strategies 2 and 3 (education, surveillance) optional.
This funding opportunity from the CDC's National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) aims to improve awareness and knowledge of Alpha-gal Syndrome (AGS), an emerging tick-borne allergy to mammalian meat and byproducts, in the United States. The cooperative agreement will support projects that form professional networks, develop educational materials, and conduct enhanced surveillance to address gaps in AGS awareness, diagnosis, and patient care. The program's three main strategies are:
Applicants must address Strategy 1 (SHARE) in their proposals; Strategies 2 (EDUCATE) and 3 (TRACK) are optional.